• Erlotinib (NSC 718781): Mechanistic Insights and SCUBE3 Inte

  2026-05-25

  Explore Erlotinib's unique mechanism as an EGFR tyrosine kinase inhibitor and discover how SCUBE3-driven oncogenic signaling impacts assay design and resistance research. This article provides advanced, actionable insights for translational cancer biology.

• Mutant p53 Reactivation via TRAP-1: Mechanistic and Method I

  2026-05-24

  The reference study introduces TRAP-1, a small molecule that selectively reactivates the p53Y220C cancer mutant by inducing proximity with BRD4, restoring mutant p53’s transcriptional activity. This approach demonstrates a structurally informed strategy for repurposing dysfunctional tumor suppressors and provides a platform for further investigation in targeted cancer therapies.

• Fzd5 Links Cholesterol Metabolism to Wnt/β-Catenin Signaling

  2026-05-23

  This study uncovers the unique ability of Frizzled5 (Fzd5) to bind cholesterol and facilitate its palmitoylation, a process essential for Wnt/β-catenin signaling and pancreatic cancer growth. The findings reveal a direct molecular bridge between aberrant cholesterol metabolism and oncogenic signaling, highlighting Fzd5 as both a cholesterol sensor and a potential therapeutic target.

• ECL Chemiluminescent Substrate Detection Kit: Enhanced Sensi

  2026-05-22

  The Enhanced ECL Chemiluminescent Substrate Detection Kit from APExBIO streamlines high-sensitivity western blot chemiluminescence detection, enabling reliable quantification of low-abundance proteins. Its robust signal duration and exceptionally low background make it indispensable for advanced protein immunodetection and signal amplification workflows.

• Vemurafenib (PLX4032): Systems Biology Insights for Melanoma

  2026-05-22

  Explore how Vemurafenib (PLX4032) advances melanoma research by integrating systems biology and multi-omics to dissect resistance mechanisms. Gain practical assay insights and learn how this BRAF inhibitor shapes the future of cancer biology.

• CXCL5 Depletion Enhances Anti-PD-1 Response in Obese PDAC Mo

  2026-05-21

  This study demonstrates that tumor-derived CXCL5, upregulated by adipose-driven IL-1β and TNF signaling, suppresses T cell infiltration and limits anti-PD-1 immunotherapy efficacy in obese pancreatic cancer models. Depleting CXCL5 in vivo enhances CD8+ T cell infiltration and sensitizes tumors to checkpoint blockade, suggesting a new strategy for improving immunotherapy in obesity-associated PDAC.

• NMDA (N-Methyl-D-aspartic acid): Precision Modeling in Retin

  2026-05-21

  Explore how NMDA (N-Methyl-D-aspartic acid) enables highly controlled modeling of retinal neurodegeneration and ferroptosis for advanced glaucoma research. This article offers a unique, protocol-driven perspective grounded in recent breakthroughs.

• EZ Cap™ Firefly Luciferase mRNA: Enhanced Reporter Workflows

  2026-05-20

  The EZ Cap™ Firefly Luciferase mRNA with Cap 1 structure offers robust, sustained bioluminescent reporting—outperforming conventional IVT mRNAs in stability and translational efficiency. Discover protocol insights, troubleshooting strategies, and how the latest LNP formulation science from the reference study can maximize your mRNA delivery and gene regulation assays.

• Scenario-Driven Best Practices with Sodium Picosulfate (SKU

  2026-05-20

  This authoritative guide delivers scenario-based solutions for common laboratory challenges in cell viability, cytotoxicity, and gut–liver axis research using Sodium Picosulfate (SKU B2027). Drawing on validated protocols and quantitative data, it demonstrates how APExBIO’s high-purity Sodium Picosulfate ensures reproducibility, workflow efficiency, and data integrity across experimental designs.

• Cannabidiol Attenuates Orofacial Inflammatory Pain via Endoc

  2026-05-19

  This study demonstrates that cannabidiol (CBD) alleviates both the sensory and affective dimensions of orofacial inflammatory pain in mouse models by modulating peripheral and central endocannabinoid signaling. These findings provide mechanistic insight into the therapeutic potential of targeting the endocannabinoid system for comprehensive pain management and related emotional comorbidities.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Protocols & QC Guid

  2026-05-19

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody addresses the need for sensitive and specific detection of goat IgG in fluorescence-based assays such as ICC/IF, IHC, flow cytometry, and ELISA. Researchers should use this reagent when employing goat-derived primary antibodies and require robust signal amplification; it should not be used for detection of non-goat immunoglobulins or in non-fluorescent workflows.

• Optimizing Organoid and Disease Models with DAPT (GSI-IX)

  2026-05-18

  DAPT (GSI-IX) empowers researchers to precisely dissect Notch signaling and amyloid precursor protein processing in complex cellular models, from hiPSC-derived organoids to translational neurodegenerative and cancer assays. APExBIO’s validated γ-secretase inhibitor delivers reproducible, high-impact results across diverse experimental workflows.

• (+)-Bicuculline: Technical Guidance for GABAA Antagonist Use

  2026-05-18

  (+)-Bicuculline is a classical GABAA receptor antagonist used to dissect inhibitory neurotransmission and synaptic NMDA receptor signaling in neuroscience research. This reagent is not suitable for diagnostic or clinical applications, and its reliability hinges on precise solubilization and storage practices.

• SIRT1/2 Inhibitor IV (cambinol): CNS & Tumor Protocol Innova

  2026-05-17

  SIRT1/2 Inhibitor IV (cambinol) empowers researchers to dissect NAD-dependent deacetylase pathways in cancer and CNS injury models, now with actionable workflows informed by breakthroughs in lactylation-regulated astrocyte polarization. Discover protocol enhancements, troubleshooting strategies, and translational applications that set this inhibitor apart for both in vitro and in vivo research.

• BRD4 Inhibition Enhances Erastin-Induced Ferroptosis via ROS

  2026-05-16

  This study establishes that BRD4 inhibitors, including I-BET-762, broadly sensitize diverse cancer cell lines to erastin-induced ferroptosis by promoting ROS accumulation and downregulating FSP1. The mechanistic findings clarify the interplay between BET inhibition and ferroptosis, providing strategic insights for cancer biology research and therapeutic development.

14450 records 1/964 page Next 12345 下5页 Last page